 | | Vol. 14.09 – 9 March, 2023 |
| |
|
|
| Exploiting in vitro and in vivo human and murine prostate cancer (PCa) models, researchers showed that RSL3 induced ferroptosis in PCa cells and demonstrated for the first time that iron supplementation significantly enhanced intracellular stress leading to cancer cell death.
[Cell Death Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| 17α-linked C2-symmetric testosterone dimers and their corresponding 17α-allyl precursors were tested for antiproliferative activity on androgen–dependent and androgen–independent prostate cancer cell lines.
[European Journal Of Medicinal Chemistry] |
|
|
|
| Investigators demonstrated the potent anti-tumor activity and molecular mechanism of capilliposide B both in vitro and in vivo.
[Phytotherapy Research] |
|
|
|
| Scientists reported that the elevation of SKP2 and EP300 transcriptomic expression is a hallmark of castration-resistant prostate cancer.
[Neoplasia] |
|
|
|
| Researchers suggested that overexpression of downstream of kinase 3 (DOK3) promoted prostate cancer progression by activating the NF-κB signaling pathway.
[Chinese Medical Journal] |
|
|
|
| Investigators explored the anti-tumor role and potential mechanism of Qingdai decoction on prostate cancer.
[Journal Of Ethnopharmacology] |
|
|
|
| Upregulated actin-related protein 2/3 complex subunit 5 (ARPC5) was observed in prostate cancer tissues and cells, as well as forecasted poor prognosis in patients.
[Apoptosis] |
|
|
|
| Scientists evaluated the photodynamic laser therapy effect, using methylene blue as a photosensitizer, in human prostate tumor cells.
[Photochemical & Photobiological Sciences] |
|
|
|
| Gene expression in prostate tissues was determined using RNA-sequencing datasets, and the gene diagnostic and prognostic values of castration-resistant prostate cancer were analyzed using bioinformatics.
[Genomics] |
|
|
|
|
| The authors describe the history of vaccines as treatments for prostate cancer and discuss vaccines that have been assessed in phase III clinical trials, as well as other vaccines and combination approaches that have been tested or are currently being evaluated in clinical trials.
[Nature Reviews Urology] |
|
|
|
| Investigators review the recent advance on 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) inhibitors and targeting 3βHSD1 for prostate cancer management.
[The Prostate] |
|
|
|
|
| Antev, Ltd. announced that the US FDA provided written guidance on the company’s proposed Phase III pivotal trial design to treat prostate cancer in patients with increased cardiovascular risk, addressing a significant need for prostate cancer drugs with a better cardiac toxicity profile.
[Antev, Ltd.] |
|
|
|
|
| March 31, 2023
Amsterdam, The Netherlands |
|
|
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | The Henry Ford Health System – Detroit, Michigan, United States |
|
|
|
| | Vancouver Prostate Centre – Vancouver, British Columbia, Canada |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
